From Deep Tech to MedTech: Pat Kelly Discusses the Future of the Seizure Patch on the Odelle Technology Podcast

Our Co-Founder and CEO, Pat Kelly, recently sat down with Steven Haken from Odelle Technology for an insightful discussion on the origins of Remagine Labs and our mission to transform drug delivery for chronic conditions.

In this episode, Pat dives into the engineering behind our "electro-pharmaceutical" platform—specifically how we are using iontophoresis to replace the burden of daily pills with a programmable, wearable patch.

Key takeaways from the conversation:

• Limits of Oral Medications: Why oral medications make it difficult for patients to adhere to their treatment, and create a "seesaw" effect of peaks and troughs in blood plasma, which may lead to side effects and breakthrough seizures.

• The Solution: How our electronically controlled patch offers a patient-friendly alternative with steady-state delivery and smart monitoring features.

• The Roadmap: Our progress toward First-in-Human clinical trials planned for 2026.

This work wouldn't be possible without the support of our incredible partners. A special thank you to the University of Melbourne, Monash University, Breakthrough Victoria, AK Clinical Research, and the Australian Department of Industry, Science and Resources for backing this vision.

Watch the full interview here.